


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+23.88%
+80.15%
-3.48%
-6.43%
SNY
Sanofi
$46.91

Login to see Sanofi (SNY) Stock IQ rating
Get instant clarity on whether to Buy, Hold, or Avoid.
Strengths

Earnings are forecast to grow

Expands stock buyback program

Trading below its fair value

Upgraded on attractively valued
SNY Price Performance
$46.6 (+0.67%)
$45.77 (+2.49%)
$49.88 (-5.95%)
$52.13 (-10.01%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a weak earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Expands stock buyback program
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
SNY Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
SNY Street Sentiment is extremely bullish and have positive views on the near-term outlook
SNY has Low risk level
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Today
Downgrade
Neutral
BNP Paribas
Apr 20, 2026
Upgrade
Neutral
Morgan Stanley
Feb 12, 2026
Downgrade
Neutral
BofA
Jan 26, 2026
Downgrade
Neutral
UBS
Jan 12, 2026
Downgrade
Equal
Barclays
MRK
Merck Company
111.86
-2.50%
REGN
Regeneron Pharmaceuticals
738.38
-3.50%
PFE
Pfizer
26.75
+0.28%
ABBV
AbbVie
198.19
-1.14%
LLY
Eli Lilly and
882.28
-3.92%
What is SNY current stock price?
What are SNY stock strengths?
What is SNY Risk Level?
What is SNY market cap and volume?
What is SNY current Stock IQ?
Should I buy SNY stock right now?
Is SNY a Strong Buy right now?
What does a 'Strong Buy' rating mean for SNY?
What does a 'Strong Sell' rating mean for SNY?
What factors influence SNY's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
SNY
Sanofi
Current Price
$46.91
Runners Also Watch
MRK
Merck Company
111.86
-2.50%
REGN
Regeneron Pharmaceuticals
738.38
-3.50%
PFE
Pfizer
26.75
+0.28%
ABBV
AbbVie
198.19
-1.14%
LLY
Eli Lilly and
882.28
-3.92%

SNY Price Performance
$46.6 (+0.67%)
$45.77 (+2.49%)
$49.88 (-5.95%)
$52.13 (-10.01%)
SNY Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a weak earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Expands stock buyback program
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
SNY Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
SNY Street Sentiment is extremely bullish and have positive views on the near-term outlook
SNY has Low risk level
Average key support and resistance price levels
Overall Wall Street Rating
SNY Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Expands stock buyback program

Trading below its fair value

Upgraded on attractively valued
SNY Trading Signals
SNY crossed its moving average. Current price: $46.91, MA20: $46.50, MA50: $46.62.
SNY has a bearish MACD crossover with MACD (0.27) crossing below Signal (0.31). This signals negative momentum shift.
SNY has positive earnings news: Beat Estimates. FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat. French drugmaker Sanofi SA (NASDAQ: SNY ) and its partner Regeneron Pharmac...
SNY has positive earnings news: Beat Estimates. Sanofi beats Q1 estimates. reaffirms FY26 outlook....
SNY has positive earnings news: Earnings Increase. Sanofi Profit Rises on Blockbuster Drug in Lift for Incoming CEO. Sanofi reported better-than-expected profit in a boost for incoming Chief Executive ...
SNY has positive earnings news: Beat Estimates. Sanofi Leans On Dupixent For First-Quarter Beat A Week Ahead Of New CEO....
SNY beat earnings expectations. Sanofi beats Q1 estimates. reaffirms FY26 outlook....
SNY beat earnings expectations. Sanofi Leans On Dupixent For First-Quarter Beat A Week Ahead Of New CEO....
SNY beat earnings expectations. FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat. French drugmaker Sanofi SA (NASDAQ: SNY ) and its partner Regeneron Pharmac...
SNY received an analyst sell rating. BNP Paribas Downgrades Sanofi (SNY) with ‘.Unlikely Near-Term Rerating’.. Sanofi (NASDAQ: SNY ) is included among the 10 Best Global Stocks ...
SNY is trading 26.70% below analyst target price of $59.44, suggesting significant upside potential
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.